Status:
TERMINATED
A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The first purpose of this study is to determine how the body absorbs, metabolizes, and eliminates a single dose of BMS-275183 (labeled with radioactive carbon). Secondly, to measure the levels of BMS-...
Eligibility Criteria
Inclusion
- Non-hematological malignancy that has progressed on standard therapy
- No more that 3 prior chemotherapies given for advanced cancer
- Adequate renal, hepatic and hematologic function
Exclusion
- Uncontrolled or significant pulmonary or cardiovascular disease
- Active Brain metastases
- Inability to swallow capsules
- Serious uncontrolled medical disorder or active infection
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00326131
Start Date
April 1 2006
Last Update
March 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
San Antonio, Texas, United States